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Background and purpose According to the treatment of
Wilm’s tumours, two different therapeutic strategies were
established in the second half of the last century. Both
National Wilm’s Tumour Study (NWTS) group and the
International Society of Paediatric Oncology (SIOP) have
helped to improve the clinical management and outcome
of patients with Wilm’s tumours. In this study, we compared
three groups of patients with Wilm’s tumours from different
racial backgrounds and therapeutic strategies.
Patients and methods A clinicopathological review was
carried out for 40 patients treated at Kyushu University
Hospital in Japan from 1960 to 2006 according to NWTS, 79
patients treated at the South Egypt Cancer Institute from
2002 to 2009 according to the SIOP protocol and 33
patients treated at the Pediatric Surgery Department of
Assiut University Hospital from 2000 to 2009 according to
the NWTS protocol.
Results In the Kyushu University group, a favourable
histology was diagnosed in 80% of patients and an
unfavourable histology in 20% of patients. The distribution
of the clinical stage was as follows: I = 40%, II = 22.5%,
III = 22.5%, IV = 7.5% and V = 7.5%. The 5-year overall
survival was 82.5%, with the 5-year stage-related survival
as follows: I = 93.7%, II = 83.3%, III = 62.5%, IV = 33.3% and
V = 100%. In the South Egypt Cancer Institute group,
favourable histology was diagnosed in 89.9% of patients,
unfavourable histology in 8.8% of patients and benign
disease in 1.3% of patients. The distribution of the clinical
stage (before and after chemotherapy) was as follows:
I = 25.3%-50%, II = 19%-20%, III = 35.4-15%,
IV = 12.5%-5% and V = 7.6%-7.6%. No case of
intraoperative tumour rupture was recorded. The overall
5-year survival rate of 84% with a 5-year stage-related
survival was as follows: I = 92%, II = 80%, III = 50%,
IV = 31% and V = 30%. In the Assiut University group, a
favourable histology was diagnosed in 79% of patients and
an unfavourable histology in 9% of patients. The
distribution of the clinical stage was as follows: I = 39.4%,
II = 21.2%, III = 21.2%, IV = 12% and V = 6%. The overall
5-year survival rate was 77% and the 5-year stage-related
survival was as follows: I = 85%, II = 75%, III = 52%,
IV = 33% and V = 33%.
Conclusion The Egyptian patients with Wilm’s tumour
presented at a younger age and had less incidence of an
unfavourable histology compared with Japanese patients.
Preoperative chemotherapy increased the rate of stage I
disease and decreased the incidence of intraoperative
tumour rupture and relapse. However, there was a
possibility that chemotherapy had been administered
in the case of benign disease. Ann Pediatr Surg
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Introduction
Renal tumours account for about 12% of childhood
tumours [1]. Wilm’s tumour is the most common renal
tumour of infancy and childhood. Its incidence varies
according to race, from 2.5 per million Chinese to 10.9 per
million American black children [2]. It is most usually a
unilateral disease, but in 5–10% of cases, both kidneys are
affected [3].
Over the past two decades, there has been a significant
improvement in the survival of children with cancer in
general and those with Wilm’s tumours in particular; this
is largely attributed to multicentric prospective studies
carried out by the National Wilm’s Tumour Study
(NWTS) group and the International Society of Paedia-
tric Oncology (SIOP) [4].
The timing of surgery in relation to chemotherapy is
still controversial in the management of patients with
Wilm’s tumours. According to the NWTS protocol, these
children should be treated first by surgery, followed by
chemotherapy with or without radiotherapy, depending
on the stage [5]. The SIOP group, in contrast, advocates
preoperative chemotherapy, followed by surgery. This
approach is an attempt to decrease the size of the tumour
and thus reduce the risk of intraoperative rupture;
however, the survival in both groups is similar [6].
Here, we report the characteristics of Wilm’s tumours and
the results of the multimodality treatment in three
groups of patients with Wilm’s tumours from different
racial backgrounds and different therapeutic strategies.
For the Kyushu University (KU) group, the NWTS
approach was used during the period 1960–2006, for the
Assiut University (AU) group, the NWTS approach was
used during the period 2000–2009 and for the South
Egypt Cancer Institute (SECI) group, the SIOP approach
was used during the period 2002–2009.
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Patients and methods
For the Kyushu University Hospital group, a retrospective
study was carried out in 40 patients treated according to
NWTS and JWiTS (Japanese Wilm’s tumour Study since
1996) group protocols during the period from 1960 to
2006. Immediate nephrectomy was performed wherever
the surgeons believed that the approach was feasible; in
those cases where the patient had a tumour that was
deemed unresectable, and in those with bilateral, inferior
vena cava malignant thrombus and distant metastasis,
preoperative chemotherapy was provided.
For the AU group, a retrospective study was carried out of
33 patients treated at the Pediatric Surgery Department
of Assiut University Hospital Egypt from 2000 to 2009
according to the NWTS protocol.
For the SECI, a prospective study was carried out in
patients with Wilm’s tumours admitted at the Paediatric
Oncology Department during the period between January
2002 and January 2009 and treated according to the SIOP-
based protocol; during this period, 79 patients were
admitted with a clinical and radiological diagnosis of Wilm’s
tumour and treated according to the SIOP-based protocol.
The medical records of patients were reviewed for age
at diagnosis, sex, incidence, presenting symptoms, pre-
operative chemotherapy treatment, type of surgery,
histopathological diagnosis, stage (on the basis of the
NWTS and JWiTS staging system for the Kyushu and
Assiut Universities groups and the SIOP staging system
for the SECI group) and final outcome.
Approval was obtained from the institute review board of
the participating centers.
Operative technique
A transverse supraumbilical muscle cutting transperito-
neal incision, and exploration of the liver, spleen,
peritoneal surface and contralateral kidney for the
presence of metastasis and a synchronous Wilm’s tumour
were performed. Mobilization of the colon and mesentery
medially and early ligation of the vascular pedicle before
extensive mobilization of the tumour is recommended if
possible. Ligation of artery and vein separately and the
artery before the vein, radical nephrectomy and para-
aortic lymph node sampling were performed.
Radiotherapy
Radiotherapy doses and indications are as follows: 10.8 Gy to
the flank for stage III favourable histology, I–III focal
anaplasia, I–II diffuse anaplasia, I–III clear cell and 19.8 Gy
to the flank for stage III diffuse anaplasia, I–III rhabdoid.
Whole-abdomen radiation should be performed if there is
diffuse tumour spillage, preoperative or intraperitoneal
tumour rupture, peritoneal tumour seeding and cytology-
positive ascites. Gross residual disease after surgery should
receive a 10 Gy boost. In cases with lung metastasis, we
administered 12 Gy to the whole lung in eight fractions; for
brain metastasis, 30.6 Gy to the whole brain in 17 fractions;
for liver metastasis, 19.8 Gy to the whole liver in 11 fractions;
for bone metastasis, 25.2 Gy to the lesion plus a 3 cm margin
and 19.8 Gy for unresected lymph node metastasis.
Results
A retrospective study was carried out of 179 patients with
Wilm’s tumour registered at the KU, AU and SECI during
the study period; 73 patients were treated with primary
nephrectomy according to the NWTS-based protocol in
Kyushu and Assiut Universities and 79 patients were
treated with preoperative chemotherapy according to the
SIOP-based protocol in SECI.
Kyushu University group data
This group included 42 patients treated at the Pediatric
Surgery Department, KU Hospital, Japan, during the
period from 1960 to 2006. Two patients were excluded
from the study because the postoperative histopatholo-
gical diagnosis was renal cell carcinoma. This group was
treated according to NWTS, where primary nephrectomy
was performed first, followed by chemotherapy and/or
radiotherapy. Some patients in this group were subjected
to preoperative chemotherapy because of the presence of
massive, bilateral tumours, inferior vena cava malignant
thrombus or distance metastases. There were 21 males
and 19 females, with a male to female ratio of 1.1 : 1. The
age of the patients ranged from 2 months to 10.5 years,
mean age 36 months. Nineteen patients (47.5%) were
younger than 2 years of age and 72.5% were younger than
4 years of age at the time of diagnosis. The tumour was
localized in the left kidney in 22 (55%) patients, the right
kidney in 15 (37.5%) and was bilateral in three (7.5%).
The mode of presentation in this group is shown
in Table 1.
The stage distribution of patients treated in Kyushu
University Hospital was as follows: 16 (40%) patients
presented with stage I disease, nine (22.5%) presented
with stage II disease, nine (22.5%) presented with stage
III disease, three (7.5%) presented with metastatic
disease and three (7.5%) had synchronous Wilm’s tumour.
The pathology of childhood renal tumours in the patients
treated in KU is shown in Table 1; in 33 (82.5%) patients,
the histopathological diagnosis was nephroblastoma with
a favourable histology and seven (17.5%) had an
unfavourable histology. Intraoperative tumour rupture
occurred in six patients (15%).
Incomplete resection was encountered in nine (23%) of
40 patients. Seven (77.7%) of these patients developed
postoperative relapse; five (71.5%) of these patients died
because of their disease.
Among 40 patients, seven (17.5%) died during the course
of follow-up; four (57%) of them had an unfavourable
histopathology (three with a rhabdoid tumour of the
kidney and one with clear cell sarcoma of the kidney).
The 5-year overall survival rate of patients treated in
Kyushu University Hospital was 82.5%. The stage-related
survival was as follows: 93.7% for stage I, 88.8% for stage
II, 66.6% for stage III, 33.3% for stage IV, and 100% for
stage V.
South Egypt Cancer Institute group data
During the period from January 2002 to January 2009,
79 patients with Wilm’s tumour were admitted to the
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hospital and received preoperative chemotherapy accord-
ing to the SIOP-based protocol. There were 40 males and
39 females. The male to female ratio was 1 : 1.
Their ages ranged from 7 months to 5 years, mean age 24
months. Forty seven (59.5%) of the patients were below 2
years at the time of diagnosis. The modes of presentation
of patients with Wilm’s tumour in this group are shown
in Table 1, 85% of the patients presented with an
abdominal mass and/or distention. In thirty (38%)
patients, the Wilm’s tumour was located in the right
kidney, in 43 (54.4%) patients, the Wilm’s tumour was
located on the left side and in six (7.6%) patients,
synchronous Wilm’s Tumours were reported.
The distribution of the clinical stage (before and after
chemotherapy) was as follows: I = 25.3%-50%, II =
19%-20%, III = 35.4-15%, IV = 12.6%-5% and
V = 7.6%-7.6% (Fig. 1); there was an increase in the
number of patients with stage I disease after chemother-
apy. The pathology is shown in Table 1.
Incomplete resection was encountered in three patients
(4%) and relapse occurred in four (5%). With a median
follow-up of 70 months, the 5-year overall survival was
84%. When all patients are considered (without exclusion
of patients lost follow up) and when abandonment
included the overall survival was 80%.
The 5-year stage-related survival was as follows: stage I
(92%), stage II (80%), stage III (50%), stage IV (31%)
and stage V (30%).
Assiut University group data
During the period from January 2000 to January 2009, 33
patients were treated at the Pediatric Surgery Depart-
ment of Assiut University Hospital according to the
NWTS protocol. The age of the patients ranged from 1–9
years; 17 (51.5%) patients were below 2 years at the time
of diagnosis. The mean age at diagnosis of patients was
2.5 years; the male to female ratio was 1 : 1.2. The tumour
was localized in the left kidney in 13 (39.4%) patients,
the right kidney in 17 (51.5%) patients and a synchronous
bilateral Wilm’s tumour was present in three (9%)
patients. The most common presenting symptom at
diagnosis was an abdominal mass and/or abdominal
distension, 82%. The distribution of the clinical stage
was as follows: stage I (33.3%), stage II (21.2%), stage III
(27.3%), stage IV (12%) and stage V (6%).
Intraoperative tumour rupture was encountered in seven
(21%) patients; three of these developed recurrence.
Incomplete resection was reported in 10 (30%) patients;
four of these developed recurrence.
The pathological diagnosis is shown in Table 2. Post-
operative recurrence was reported in seven (21.2%)
patients. The 5-year overall survival was 77%. The 5-year
stage-related survival as follows: I = 85%, II = 75%, III =
52%, IV = 33% and V = 33%.
Discussion
Wilm’s tumour is the most common embryonic malig-
nancy of renal origin [6]. The survival rate of children
with Wilm’s tumours has improved considerably since the
prospective randomized trials conducted by the NWTSG,
SIOP and the UKCCSG. Although the overall manage-
ment of children with Wilm’s tumours is one of the great
success stories in cancer therapy and currently more than
90% of children survive 4 years after their diagnosis, there
is still room for improvement [7].
The median age in our series was 3, 2.5 and 2 years for the
KU group, the AU group and the SECI group, respec-
tively, which is almost the same as that reported in other
series [8–15]. More than 59.5% of SECI patients, 47.5%
of KU patients and 51.5% of AU patients are below 2 years
at presentation, whereas 95, 72.5 and 84.8% of SECI, KU
and AU groups, respectively, are below 4 years at
Table 1 Clinical characteristics and outcome of patients with












0–23 19 (47.5%) 17 (51.5%) 47 (59.5%)
24–47 10 (25%) 11 (33.3%) 28 (35.5%)





Male 21 (52.5%) 15 (45.5%) 40 (50.5%)
Female 19 (47.5%) 18 (54.5%) 39 (49.5%)
Site
Right 15 (37.5%) 13 (39.4%) 30 (38%)
Left 22 (55%) 17 (51.5%) 43 (54.4%)
Bilateral 3 (7.5%) 2 (6%) 6 (7.6%)
Histopathology
Favourable 33 (82.5%) 30 (91%) 71 (89.9%)
Anaplastic 1 (2.5%) 1 (3%) 4 (5.1%)
Rabdoid tumour 3 (7.5%) 1 (3%) 2 (2.5%)
Clear cell sarcoma
of the kideny
3 (7.5%) 1 (3%) 1 (1.3%)
Benign disease 0 0 1 (1.3%)
Pretreatment staging
Stage I 16 (40%) 13(39.4%) 20 (25.3%)
Stage II 9 (22.5%) 7 (21.2%) 15 (19%)
Stage III 9 (22.5%) 7 (21.2%) 28 (35.4%)
Stage IV 3 (7.5%) 4 (12.1%) 10 (12.6%)
Stage V 3 (7.5%) 2 (6%) 6 (7.6%)
Tumour rupture 6 (15%) 7 (21.2%) 0 (0%)
Incomplete resection 9 (23%) 10 (30%) 7 (8.8%)
Recurrence 7 (18%) 7 (21.2%) 8 (10%)
Overall survival 33(82.5%) 77% 84%
AU, Assiut University; KU, Kyushu University; NWTS, National Wilm’s Tumour
Study; SIOP, International Society of Paediatric Oncology; SECI, South Egypt
Cancer Institute.
Fig. 1
Prechemotherapy and postchemotherapy staging of South Egypt
Cancer Institute group.
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presentation; these are in agreement with the results of
Weirch et al. [16]. Although Grabois and Mendonca [17]
and Carli et al. [18] reported age below 2 and 4 years as
follow 22.7%, 55.3% and 11%, 74.2%, respectively [16,17].
The age of Egyptian patients is younger than Japanese
patients; this may be because of racial and genetic causes,
but in both groups, the age of most patients is below 4
years, which is similar to that reported in previous studies.
The sex ratio in the current study was the same for both
Japanese and Egyptian patients, which is similar to that
reported in most other series [8,11,19–21], although the
sex ratio reported from some developing countries shows
a slight male predominance [9,10,13,14].
The main presenting symptom of our study was an
abdominal mass and/or distension, found in 72% of
KU patients, which is similar to that reported in the first
Wilm’s tumour study of UKCCSG and a study from a
South African Center; these rates were 74 and 77%,
respectively [22,23], however, in SECI patients and AU
patients the abdominal mass as presenting symptoms are
85% and 82% respectively, these rates were similar to rate
reported by other studies [9,15]. However, Yildiz et al. [8]
(Turkey) and Madani et al. [10] (Morocco) reported a 95%
and 97% rate of presence of an abdominal mass as pre-
senting symptoms, respectively. There is a higher incidence
of an abdominal mass and/or distension in SECI and AU
patients; this may be because of a delayed diagnosis.
The stage I percentage in our study was 50% for the SECI
group (postchemotherapy), 40% for the KU group and
33.3% for the AU group; this difference was because
of the preoperative chemotherapy treatment that was
provided for SECI patients. The percentage of stage I for
SECI patients is almost the same as that reported in
Morocco by Madani et al. (50%) [8] and slightly lower
than the rate reported in some SIOP series, which is
greater than 60% [19,24], but greater than other SIOP
series, which is less than 40% [17,25]. Sidhom et al. and
Zaghloul et al. (National cancer Institute, Cairo Uni-
versity) reported a 21.4% and a 22.3% percentage of stage
I in Egyptian patients, respectively, treated according to
NWTS [26,27]. However, the percentages of stage I in
KU and AU patients are similar to those in other studies
reported by Pianezza et al. (Ontario, Canada) [15] and
higher than those reported by Davidson et al. (South
Africa) and Grabois et al. (Brazil): 30.3% and 19.7%,
respectively, on the basis of NWTS [12,16]. From the
above result, we can conclude the importance of
preoperative chemotherapy in downstaging of Wilm’s
tumours (downstage of higher stages to stage I so increase
the incidence of stage I disease) subsequently easier
surgery and can achieve complete surgical resection.
In our study, tumours were localized in the left kidney in
55% of patients and in 51.5 and 54.4% of Japanese and
Egyptian patients, respectively; there was no statistically
significant difference and this was similar to that in previous
studies that reported that the left kidney was involved more
frequently than the right kidney [10,28–32].
Three KU patients (7.5%) and two AU patients (6%) had
a bilateral renal tumour. However, six SECI patients
(7.6%) had a bilateral renal tumour; previous studies have
reported the incidence of bilateral Wilm’s tumours to
range from 4 to 10% [10,14,15,17,27,33–35].
Histopathologically, 17.5% of KU, 8.8% of SECI and 9% of
AU patients had an unfavourable histology. In NWTS3, the
rate of an unfavourable histology was 11.2% [36]. In contrast,
in the SIOP-9/GPOH study, the rate of the presence of an
anaplastic Wilm’s tumour was 7.5% [18]. There is a higher
incidence of an unfavourable histology among Japanese
patients; the exact cause for this is unknown, but a study
carried out at Shanghai Children’s Medical Center, China,
reported that the incidence of Wilm’s tumours with an
unfavourable histology (including anaplasia, clear cell
sarcoma and rhabdoid tumours) was 30%.
Slightly more than 1% (one patient 1.3%) of the patients
in the SECI group received the wrong preoperative
chemotherapy for benign disease (xanthogranulomatous
pyelonephritis); SIOP studies have reported that, if a
tumour has typical imaging and clinical features of a
Wilm’s tumour, chemotherapy should be started without
histological confirmation. Thus, 1% of children with a
noncancerous renal lesion receive chemotherapy [37].
The UKW3 trial reported that 12% of renal tumours with
typical features of Wilm’s tumours on imaging studies
were found to be non-Wilm’s tumours on a prechemo-
therapy biopsy [38]. On SIOP 93-01, approximately 5%
of lesions in patients treated with chemotherapy were
ultimately found not to be Wilm’s tumours and 1.8% of
lesions were found to be benign [39]. Xanthogranuloma-
tous pyelonephritis is rare in children and is difficult to
diagnose preoperatively, especially when the signs of
sepsis are not prominent [40]; also, preoperative chemo-
therapy may induce pathological changes similar to the
pathology picture of xanthogranulomatous pyelonephritis.
However, all patients in the KU and AU groups were
accurately diagnosed histopathologically and a proper
postoperative management was initiated.
In the SECI group, in patients treated by preoperative
chemotherapy on the basis of the SIOP protocol, the
incidence of intraoperative tumour rupture was 0%,
whereas in Japanese patients treated according to the
NWTS protocol, the incidence was 15 and 21% in AU.
The UKW3 reported that there were no tumour ruptures
among the 102 patients in the preoperative chemother-
apy group compared with 15 (14.7%) among the 103
patients randomized to immediate nephrectomy [41].
This result shows the importance of preoperative che-
motherapy in minimizing intraoperative tumour spillage.
Table 2 Preoperative chemotherapy regimen for the South Egypt
Cancer Institute group
Week
1 2 3 4 5 6
Clinical and radiological stages I and II: two drugs for 4 weeks
Vincristine (1.4 mg/m2, intravenously) V V V V – –
Dactinomycin (45 mg/kg, intravenously) A – – A – –
Clinical and radiological stages III, IV, V: for 6 weeks
Vincristine (1.4 mg/m2, intravenously) V V V V V V
Dactinomycin (45 mg/kg, intravenously) – A – – A –
Doxoroubocin (20 mg/m2, intravenously) – D – – D –
Babies < 12 months of age received one-half the recommended dose of all drugs.
D, Dactinomycin; V, Vincristine.
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In SECI patients, the incidence of incomplete resection
was 10% and the rate of recurrence was 5%. In the KU
group, incomplete resection was encountered in nine
(22.5%) of 40 patients; three (33.3%) of these patients
died and two of them developed postoperative recur-
rence. Among 40 patients, seven (17.5%) died during the
course of follow-up and four (57%) had an unfavourable
histopathology (three cases of a rhabdoid tumour of the
kidney and one case clear cell sarcoma of the kidney). Six
of 40 patients (15%) developed postoperative recurrence;
five of these (83%) patients died. This result is in
agreement with the reports from early studies that
reported that the long-term survival rate after recurrence
of a Wilm’s tumour hardly reached 30% [42].
The intra operative tumor rupture increase incidence of
local recurrence with its gloom outcome.
The 5-year overall survival rate for KU was 82.5 and 77% for
AU patients. When all patients are considered (without
exclusion of patients lost follow up) and when abandon-
ment included the overall survival was 80%. There was no
statistically significant difference between the two groups.
The major advantages of preoperative chemotherapy in the
treatment of Wilm’s tumours are as follows: (i) a reduction
in the dose of adjuvant chemotherapy as a result of
preoperative downstaging of the tumour; (ii) a decrease in
the incidence of intraoperative tumour ruptures; and (iii) a
reduced need for postoperative radiotherapy in cases of
metastatic disease. Besides its acute toxicity, the major
disadvantage of preoperative chemotherapy is the lack of a
valid histopathological diagnosis before beginning the
treatment, with a consequent risk of treating benign
lesions resistant to chemotherapy. However, this is
estimated to be 1.5–5% and, therefore, is acceptable when
balanced against the advantages of the strategy.
Although North America and Europe have different
philosophies on preoperative chemotherapy, the over-
riding message is that most patients with Wilm’s tumours
survive in the long term, irrespective of the sequence of
therapeutic interventions.
Conclusion
Egyptian patients with Wilm’s tumours presented at a
younger age and had a lower incidence of an unfavourable
histology compared with Japanese patients. Preoperative
chemotherapy increased the rate of stage I disease and
decreased the incidence of intraoperative tumour rupture
and relapse. However, there is a possibility that chemo-
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